Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

NICE overrules on eczema advice

Draft guidance from the National Institute for Clinical Excellence has clashed with the National Prescribing Centre's advice on eczema treatments.

The draft guidance has ruled out the use of the topical drug treatment pimecrolimus (Elidel), an immunomodulating drug, because of a lack of evidence and cost – contrary to NPC advice.

NICE has also recommended that GPs with a special interest in atopic eczema can initiate and monitor tacrolimus (Protopic) treatment whereas the NPC says only specialists should begin treatment.

Dr Stephen Kownacki, a GP in Wellingborough, North- amptonshire, and chair of the Primary Care Dermatology Society, said: 'We fear this is driven by cost rather than benefit for patients. Inevitably, new treatments cost more.'

Final recommendations from NICE are due in September.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say